Skip to main content

Psoriatic arthritis

      There has been a lot of talk lately about the difference in the way male and female PsA patients experience their disease.  Are the differences only cultural or are there important clinical differences in the disease presentation, organ involvement and complications that physicians should be aware of?   
      RT @DrCassySims: Does tofacitinib work better in patients with PsA and AS who smoke?

      Abstract #1036 #ACR22 @RheumNow

      Catherine Sims, MD DrCassySims

      2 years 9 months ago
      Does tofacitinib work better in patients with PsA and AS who smoke? Abstract #1036 #ACR22 @RheumNow 🚬519 ever smokers 🚭767 never smokers 💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO ✋Overall, efficacy was generally comparable in ever v. never 🚬
      Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.
      RT @RichardPAConway: FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to

      Richard Conway RichardPAConway

      2 years 9 months ago
      FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to benefit from TYK2i deucravacitinib @RheumNow #ACR22 Abstr#2133 https://t.co/eVq4XQgX5l https://t.co/HZlTS5OZ2s
      RT @RichardPAConway: Fleischmann et al. Safety of TYK2i Deucravacitinib in PsA/PsO in terms of labs. Really no effect on

      Richard Conway RichardPAConway

      2 years 9 months ago
      Fleischmann et al. Safety of TYK2i Deucravacitinib in PsA/PsO in terms of labs. Really no effect on lab values other than increase in trigs. Guess this is why they don't have lab monitoring on label? @RheumNow #ACR22 Abstr#2132 https://t.co/ueIVKQc6jr https://t.co/u99QE71VQ5
      RT @RichardPAConway: Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safe

      Richard Conway RichardPAConway

      2 years 9 months ago
      Warren et al. TYK2i deucravacitinib in plaque psoriasis at 2 years. Sustained efficacy. No new safety signals seen. @RheumNow #ACR22 Abstr#2134 https://t.co/5SGKKrvwbc https://t.co/ynvfZiOrsp
      RT @synovialjoints: ⇧ brain functional connectivity to the insula between the mid-posterior IC & brain areas invol

      Dr. Antoni Chan synovialjoints

      2 years 9 months ago
      ⇧ brain functional connectivity to the insula between the mid-posterior IC & brain areas involved in sensory (thalamus), learning/affective (parahippocampal gyrus), cognitive (prefrontal cortex) pain modulation in PsA. Sunzini F Abs#2256 https://t.co/5TUcOacuIS #ACR22 @RheumNow https://t.co/7IqLYzzpyA
      RT @RichardPAConway: Kavanaugh et al. TYK2i deucravacitinib in PsA. Nice breakdown of MDA and its components over 16 wee

      Richard Conway RichardPAConway

      2 years 9 months ago
      Kavanaugh et al. TYK2i deucravacitinib in PsA. Nice breakdown of MDA and its components over 16 weeks. MDA achieved 23-24% with deucravacitinib at 16 weeks vs 8% with placebo @RheumNow #ACR22 Abstr#2136 https://t.co/9IG8CeZzMh https://t.co/Vg8E20y7Z8
      RT @RichardPAConway: Mease et al. TYK2i Deucravacitinib in PsA. Phase 2 RCT 52 week results. PASDAS, DAPSA efficacy main

      Richard Conway RichardPAConway

      2 years 9 months ago
      Mease et al. TYK2i Deucravacitinib in PsA. Phase 2 RCT 52 week results. PASDAS, DAPSA efficacy maintained through week 52. No new safety concerns. @RheumNow #ACR22 Abstr#1598 https://t.co/sRKkgkYtQJ https://t.co/YMXMEH3wsq
      RT @RichardPAConway: Ogdie @AlexisOgdie et al. CorEvitas, PsA treatment after 1st line TNFi failure. Switching MOA proba

      Richard Conway RichardPAConway

      2 years 9 months ago
      Ogdie @AlexisOgdie et al. CorEvitas, PsA treatment after 1st line TNFi failure. Switching MOA probably more effective @RheumNow #ACR22 Abstr#1600 https://t.co/vy8gxDaYxZ https://t.co/NmkESbSNfL
      Best of ACR Day Two in PSA
      ×